Generation of a Jurkat-based fluorescent reporter cell line to evaluate lipid antigen interaction with the human iNKT cell receptor

Humeniuk, Piotr; Geiselhart, Sabine; Battin, Claire; Webb, Tonya; Steinberger, Peter; Paster, Wolfgang; Hoffmann-Sommergruber, Karin

doi:10.1038/s41598-019-43529-4

Download PDF

Article
Open access
Published: 15 May 2019

Generation of a Jurkat-based fluorescent reporter cell line to evaluate lipid antigen interaction with the human iNKT cell receptor

Scientific Reports volume 9, Article number: 7426 (2019) Cite this article

6075 Accesses
4 Citations
2 Altmetric
Metrics details

Subjects

A Publisher Correction to this article was published on 05 November 2019

This article has been updated

Abstract

Invariant natural killer T (iNKT) cells are a specialized subset of T cells contributing to both, the innate and adaptive immune responses. In contrast to conventional T lymphocytes they recognize lipid antigens. The aim of the project is to establish a novel model system, to study iNKT-TCR – ligand interaction. An iNKT reporter cell line (JE6-1^REP-iNKT) was engineered by introducing the human iNKT-TCR into a human leukemic T cell line carrying an NF-κB-driven fluorescent transcriptional reporter construct. Antigen presenting BW^STIM cells expressing human CD1d and CD80 were generated. Reporter induction in JE6-1^REP-iNKT cells was assessed by flow cytometry. CRISPR/Cas9 was used for β2M knock out in JE6-1^REP-iNKT cells to abrogate CD1d expression and thus excluding antigen self-presentation. Reporter cells were shown to specifically react with iNKT antigens presented via CD1d. Their sensitivity towards α-GalCer was comparable to a murine iNKT hybridoma cell line. In conclusion, we created a novel iNKT reporter platform which, compared to traditional iNKT cell assays, is characterized by a shorter turnaround time and lower costs. It thus facilitates the identification of antigenic structures that drive the activation of iNKT cells in health and disease.

Invariant NKT cells facilitate cytotoxic T-cell activation via direct recognition of CD1d on T cells

Article Open access 25 October 2019

Cell activation-based screening of natively paired human T cell receptor repertoires

Article Open access 17 May 2023

MHC class II tetramers engineered for enhanced binding to CD4 improve detection of antigen-specific T cells

Article 03 May 2021

Introduction

Natural killer T cells expressing an invariant T cell receptor α-chain (iNKT cells) are a unique and evolutionary conserved subset of lymphocytes. In contrast to conventional T lymphocytes, which recognize peptide antigens in the context of major histocompatibility complex (MHC) molecules, iNKT cells recognize lipid antigens presented by CD1d, a non-polymorphic MHC class I homolog. CD1d is expressed on many types of epithelial and endothelial cells and professional antigen-presenting cells. Invariant NKT cells exhibit characteristics of innate and adaptive immune cells and upon activation not only display killer cell activity, but also rapidly secrete large amounts of cytokines. Both, protective and pathological roles have been ascribed to iNKT cells.

In murine iNKT cells, the invariant Vα14-Jα18 TCRα chain is paired with a restricted repertoire of β chains, including Vβ2, Vβ7 and most commonly Vβ8.2, which is expressed in approximately 60% of murine iNKT cells^1,2. In C57BL/6 wild-type mice, iNKT cells are most abundant in the liver, where they represent around 22% of mononuclear cells. Lower percentages were observed in the thymus, spleen and bone marrow. In murine peripheral blood, iNKT cells constitute ~0.5% of mononuclear cells³. To facilitate research on murine iNKT cells, hybridoma cell lines were successfully generated and have proven invaluable tools to study the biology of iNKT cells^4,5,6,7. In human iNKT cells, the invariant Vα24-Jα18 TCRα chain is paired with the Vβ11 TCRβ chain⁸. In humans, the frequency of iNKT cells is usually much lower than in mice and a high degree of variability in iNKT cell numbers between individuals has been reported. In healthy individuals approximately 0.01–1% of peripheral blood mononuclear cells (PBMCs) are iNKT cells⁹.

Upon activation, iNKT cells can significantly affect immune responses by promoting the secretion of Th1, Th2 or Th17 immune regulatory cytokine patterns. Invariant NKT cells have been identified as important players in health and disease^10,11. Several studies implicated iNKT cells in immune responses against tumors¹². A beneficial role of iNKT cells was further reported in several bacterial and viral infections¹³. For example, in a mouse model for Lyme disease caused by Borrelia burgdorferi, iNKT cells showed a protective role during infection by inhibiting pathogen spreading¹⁴. Pulmonary infections with Streptococcus pneumoniae¹⁵, Pseudomonas aeruginosa¹⁶, and influenza virus¹⁷ are further examples where iNKT cells activated via CD1d antigen presentation, expand and provide the cytokine milieu to attract neutrophils and macrophages. Additionally, the importance of iNKT cells has been described in the context of obesity¹⁸ and insulin resistance¹⁹. Recent findings indicate the participation of iNKT cells in the pathomechanisms of allergy and asthma^20,21. However, whether they generally play a protective or pathological role is still under debate¹³.

Antigens for iNKT cells are present in the environment²². The first described iNKT cell antigen, α-galactosylceramide (α-GalCer), was originally purified from the deep sea sponge Agelas mauritanius and identified through its strong anti-tumor properties in mice²³. Binding of the lipid antigen to CD1d occurs via the two lipid chains, exposing the α-linked sugar group for recognition by the invariant TCR. Although the majority of mammalian glycolipids utilize a β-linkage of the sugar²⁴, most antigenic ceramide lipids show α-anomeric linkage of a galactose sugar which is crucial for its stimulatory capacity^23,25. These lipid antigens vary in their lipid tails as well as in their head group and show different affinities for both, CD1d and the TCR²⁶ and thus determining Th1/Th2 balance^27,28. Therefore, the identification of new lipid antigens is highly relevant for developing iNKT cell based therapies. Stimulation of iNKT cells with α-GalCer causes rapid production of Th1 and Th2 cytokines, including IL-4, IL-10, IL-13 and IFN-γ, thus strongly enhancing immune responses. Anti-cancer properties of α-GalCer have been tested in several preclinical and clinical studies, which showed promising results^29,30,31. The sphingosine truncated derivative of α-GalCer, OCH, is characterized by lower CD1d and iNKT-TCR affinity, and preferentially stimulates iNKT cells to produce Th2 cytokines. In a murine model of experimental autoimmune encephalomyelitis (EAE), OCH showed protective properties superior to α-GalCer³². 7DW8-5, a recently characterized analog of α-GalCer with strongly increased CD1d affinity, is characterized by a fluorinated benzene ring at the end of a shorter C8 length fatty acyl chain. 7DW8-5 shows significantly increased biological activity and was designed as a potential malaria and HIV vaccine adjuvant²⁶.

The small number of iNKT cells in human peripheral blood and the lack of human iNKT hybridoma cell lines makes it challenging to study these cells. Reliable methods of iNKT cell expansion using artificial antigen presenting cells already exist, however they are time consuming and technically complex³³.

To overcome the difficulties in studying human iNKT cells, we aimed to generate a fluorescence-based human iNKT-TCR reporter system, applicable for screening potential new lipid antigens that influence iNKT cell activation.

Results

Generation of an iNKT-TCR-transgenic reporter T cell line

We have recently described Jurkat E6.1 NF-κB::eGFP, a highly sensitive reporter T cell line allowing fluorescence-based readout of NF-κB transcriptional activity^34,35. For the current study, Jurkat E6.1 NF-κB::eGFP were transduced with the human iNKT-TCR (TCR V-alpha chain: GenBank - ABC72374.1; TCR V-beta chain: GenBank - EAW51929.1) and designated JE6-1^REP-iNKT (Fig. 1A)³⁶. 2A-peptide mediated co-expression of the iNKT-TCR α and β chains with the puromycin N-acetyl-transferase allowed efficient selection of cells containing the iNKT-TCR encoding construct. Surface expression of the iNKT-TCR in the JE6-1^REP-iNKT reporter cell line was verified by positive staining with APC-labelled α-GalCer loaded CD1d tetramers (Fig. 1B, upper panel). Parental JE6-1^REP cells lack the iNKT-TCR and as expected no specific signal with APC-labelled α-GalCer loaded CD1d tetramers was detected. Due to highly conserved sequences between murine and human CD1d, a strong cross-reactivity was observed when testing our reporter cell line with murine CD1d dextramers loaded with α-GalCer (Fig. 1B, middle panel). CD28 expression was confirmed for both, parental and iNKT-TCR-transduced reporters (Fig. 1B, lower panel). The well-established murine hybridoma cell line DN32.D3³⁷ stained positive for both, the iNKT-TCR and CD28 (Fig. 1B – right panel), in contrast to the control cell line N37-1A12³⁸, which stained positive only for CD28.

For functional testing, the reporter cells were cultivated on plate-bound CD1d loaded with α-GalCer. Over-night incubation led to robust NF-κB-driven eGFP expression, with >90% of positive cells (Fig. 1C). DN32.D3 cells cultured on similarly prepared α-GalCer-loaded CD1d surfaces responded by IL-2 production, which could be measured in the supernatant (Fig. 1D).

JE6-1^REP-iNKT display dose-dependent transcriptional reporter activation in response to α-GalCer-loaded CD1d

We first tested the sensitivity of our JE6-1^REP-iNKT reporter cells in an in vitro assay. Following overnight incubation with α-GalCer loaded human CD1d immobilized on culture plates, our reporter cells responded in a dose-dependent manner, starting at a concentration of 0.63 µg/ml CD1d (Fig. 2A, left panel). Providing a co-stimulatory signal via a soluble monoclonal CD28 antibody resulted in increased eGFP-levels, but did not enhance sensitivity. In addition, activation of the JE6-1^REP-iNKT cells was assessed via the surface expression of the early activation marker CD69 (Fig. 2A, middle panel). Upregulation of CD69 could be detected starting at a concentration of 0.63 µg/ml CD1d. Again, co-stimulation via CD28 resulted in an almost two-fold increase of CD69 expression while the sensitivity of the system remained unchanged. During this experiment, expression of the iNKT-TCR was assessed. Surface expression of the iNKT-TCR decreased in a dose-dependent manner starting already at a concentration of 0.31 µg/ml of loaded CD1d and was not detectable at concentrations of 5 µg/ml and higher (Fig. 2A, right panel). Next, the activation of our reporter cell system was tested using α-GalCer loaded murine CD1d in order to compare cross reactivity (Fig. 2B). Response to mouse CD1d complexes was comparable due to highly conserved sequences between human and mouse CD1d proteins. Co-stimulation via CD28 increased the signal of eGFP and CD69 expression. Again downregulation of surface iNKT-TCR expression was observed, starting at 0.31 µg/ml of loaded murine CD1d (Fig. 2B, left panel). As a reference, the murine hybridoma cell line DN32.D3 was tested, using IL-2 release as readout (Fig. 2C). The sensitivity of DN32.D3 was comparable to our reporter cell system with activation starting at 0.63 µg/ml of loaded CD1d. Addition of a murine CD28 antibody did not affect the response of DN32.D3 cells. Our data demonstrate that JE6-1^REP-iNKT cells are equally sensitive as the commonly used DN32.D3 hybridoma cell line.

Generation of human CD1d-expressing BW-based stimulator cells

For cellular activation assays, DN32.D3 hybridoma cells are typically incubated with lipid-loaded CD1d. To provide a more physiological stimulation, particularly for lipid antigens that require processing, a cellular CD1d-lipid presentation system would be advantageous. To this end, we introduced human CD1d and CD80 into the murine thymoma cell line BW5147 (BW). A single high expression cell clone was chosen for further experiments designated BW^STIM (Fig. 3A). BW cells are rapidly dividing suspension cells. As such they are a convenient, easy-to-use, antigen presenting cell line. Additionally, L-CD1d cells (CD1d transfected murine fibroblasts)³⁹ were analyzed for their surface expression of CD1d and CD80.

Constitutive low-level expression of murine CD1d was observed on BW cells (Fig. 3B, left panel). L-CD1d cells were highly positive for murine CD1d and CD80 and negative for human CD1d, respectively (Fig. 3B, right panel). L-vector cells (used as a control) were negative for both, human and murine CD1d and positive for murine CD80. Lipid antigen presentation by BW^STIM cells was assessed by co-culture with JE6-1^REP-iNKT cells in the presence of α-GalCer (Fig. 3C). Fluorescence microscopy of an activated reporter cell (Fig. 3D) and flow cytometry analysis of eGFP expression (Fig. 3E) demonstrated that the generated BW^STIM cell line has a strong capacity to present lipid antigens.

JE6-1^REP-iNKT cell activation in co-culture assays with BW^STIM and L-CD1d cells

Further, we tested our reporter cell line in co-culture with BW^STIM cells. Again, α-GalCer was used as lipid antigen and eGFP and CD69 expression as activation markers. Increasing concentrations of α-GalCer resulted in a dose-dependent stimulation of the reporter cells, starting at a concentration of 31 pg/ml α-GalCer (Fig. 4A) and continuously increasing up to 2,000 pg/ml without reaching a plateau. Control cultures (JE6-1^REP-iNKT/BW^PAR or JE6-1^REP/BW^STIM) did not induce cellular activation. In parallel, co-culture experiments of our stimulator cells BW^STIM and the reference cell line DN32.D3 were performed. As already observed for plate-bound CD1d, the sensitivity was comparable to JE6-1^REP-iNKT reporter cells (Fig. 4B). Alternatively, JE6-1^REP-iNKT cells were cultured with L-CD1d cells. As shown in Fig. 4C-D, L-CD1d cells endogenously expressing an activating antigen are able to stimulate both, JE6-1^REP-iNKT reporter and DN32.D3 cells, respectively. Addition of α-GalCer resulted in a dose-dependent increase of eGFP and CD69 expression starting at a concentration of 500 pg/ml. L-vector cells, used as a control, did not show an increase of eGFP and CD69 expression after addition of α-GalCer. Again, DN32.D3 hybridoma cells showed a similar sensitivity as demonstrated by increased IL-2 release.

Genetic ablation of β2 microglobulin eliminates antigen self-presentation

JE6-1^REP-iNKT cells constitutively show reporter activity upon addition of lipid antigen in the absence of antigen presenting cells as shown by upregulation of eGFP and CD69 (Fig. 5A). Dose-dependent activation was detectable starting at a concentration of 2.5 ng/ml α-GalCer. However, α-GalCer did not induce JE6-1^REP cell activation confirming that iNKT reporter cell activation is dependent on CD1d-iNKT-TCR interaction. Also the murine hybridoma cell line DN32.D3 secreted IL-2 (up to 3,500 pg/ml) after addition of α-GalCer in a dose-dependent manner. In contrast, the control hybridoma line N37-1A12 did not respond (Fig. 5B). JE6-1^REP and JE6-1^REP-iNKT cells as well as DN32.D3 constitutively express low levels of CD1d on their surface as shown by positive staining for human and murine CD1d, respectively (Fig. 5C). CD1d surface expression causes self-presentation of lipid antigens thus resulting in considerable reporter activity. In order to reduce T-T presentation we generated a β2 microglobulin knock out JE6-1^REP-iNKT cell line by CRISPR/Cas9, eliminating CD1d expression (Fig. 5D). The generated cells stained negative for CD1d (Fig. 5E) and did not display increased eGFP and CD69 expression upon addition α-GalCer (Fig. 5A). In co-cultures of α-GalCer pulsed BW^STIM cells, the sensitivity of JE6-1^REP-iNKT and JE6-1^{REP-iNKT-β2M_KO} was comparable as indicated by eGFP expression (Fig. 5F).

Jurkat iNKT reporter cells can reveal antigenic properties of various lipid antigens

We next wanted to assess whether our iNKT reporter cells can reveal differences in the stimulatory capacity of selected CD1d-presented lipid antigens. Figure 6A shows the dose-dependent activation capacities of α-GalCer and two derivatives, OCH and 7DW8-5, in co-culture assays with BW^STIM cells titrated up to 10 ng/ml. BW^PAR cells pulsed with 7DW8-5 served as negative control. 7DW8-5 induced activation of our reporter cells at the lowest concentration of 2.4 pg/ml. Cells responded in a dose-dependent manner without reaching a plateau. α-GalCer shows a similar activation curve with a reduced slope. In contrast, OCH, even at the highest concentrations, resulted in only very moderate stimulation (<30% of 7DW8-5 activation) of reporter cells. To examine the sensitivity of our JE6-1^{REP-iNKT-β2M_KO} reporter cells in more detail, we performed co-culture assays with BW^STIM cells (Fig. 6B–D), and antigen presentation assays with plate immobilized hCD1d (Fig. 6E–G). Concentration ranges of the different lipid antigens were adapted to their individual stimulation capacities in co-culture assays as presented in Fig. 6A. The same concentration ranges were used for both, BW^STIM cell pulsing and loading plate-bound hCD1d. In general, lower eGFP values were obtained with plate immobilized hCD1d (Fig. 6B–D) as compared to co-culture assays (Fig. 6E–G). JE6-1^{REP-iNKT-β2M_KO} responded to α-GalCer in a dose-dependent manner in both, co-culture and CD1d plate immobilized assays, with increased eGFP expression starting at 125 pg/ml. The highest concentrations (up to 10 ng/ml) were chosen for OCH (Fig. 6C,F) due to its lower stimulatory capacity. Although the slope was flat for OCH, differences in eGFP expression were still discernible and strictly dose-dependent. The lowest concentrations were applied for 7DW8-5 resulting in increased eGFP expression at 1.6 pg/ml and 6.3 pg/ml in co-culture and CD1d plate immobilized assay, respectively (Fig. 6D,G). Expression of eGFP was continuously increasing up to a concentration of 100 pg/ml without reaching a plateau of stimulation.

Discussion

Invariant natural killer T (iNKT) cells are a distinct lineage of lymphocytes that are involved in the pathomechanisms of many different diseases while also contributing to homeostasis. For example, iNKT cells become activated during pathogen invasion, can suppress autoimmune diseases and allograft rejection and graft-versus host disease⁴⁰. A better understanding of the diverse functions of iNKT cells is a prerequisite for the development of immunotherapeutic strategies targeting this cell lineage.

Invariant NKT cells can be grouped into different functional subsets based on characteristic surface molecules and highly divergent gene programs. Similar to conventional T helper cells, NKT1 (T-bet⁺ PLZF^lo RORγt⁻), NKT2 (PLZF^hi RORγt⁻ T-bet⁻), and NKT17 (RORγt⁺ T-bet⁻ PLZF^int) cell populations were distinguished⁴¹. Moreover, the abundancy of these subsets is tissue dependent. For example, NKT1 cells are dominant in liver, spleen, lungs, thymus and small intestine of C57Bl/6 mice. In contrast, NKT17 cells are enriched in lymph nodes¹³. Moreover, cues from the local environment play an immanent role on the recruitment and stimulation of iNKT cells.

Primary human iNKT cells are difficult to obtain due to their low numbers in the peripheral blood. This hampers studies on these cells and makes it difficult to test candidate lipid antigens. In contrast to murine iNKT cells, human hybridoma cell lines are not available. To overcome these difficulties, we developed a modular human iNKT-TCR reporter cell system, using an already established Jurkat-based cell line equipped with an NF-κB::eGFP reporter construct³⁴. Jurkat reporter cells stably transduced with the human iNKT-TCR (JE6-1^REP-iNKT) specifically reacted with α-GalCer presented in the context of CD1d (plate bound assay) resulting in a dose-dependent activation as visualized by NF-κB-driven eGFP expression. When compared with the hybridoma cell line DN32.D3, our JE6-1^REP-iNKT cells showed equal sensitivity for α-GalCer. The main advantage of the reporter cell line is the possibility to directly measure NF-κB activation via eGFP expression without any additional staining procedures, making it a simple, fast and cost-effective system.

While certain lipids such as α-GalCer can directly be loaded onto CD1d, others require processing before being loaded and presented at the cell surface. To overcome this issue, we performed co-cultures with CD1d⁺ stimulator cells. JawsII, a professional murine APC line⁴², has been shown to highly express CD1d on their surface and to efficiently present α-GalCer⁴³. When tested with our reporter cells, we found JawsII to function as APCs (data not shown). However, JawsII exhibit a slow growth rate and require addition of costly cytokines. We were therefore looking for an alternative APC cell line for our studies. Previously, we have used the rapidly dividing murine suspension cell line BW5147 to generate stimulator cells to activate primary T cells and human T cell reporters^44,45. For the current study, we transduced the parental BW5147 with human CD1d and CD80 (BW^STIM). BW^STIM are a convenient, easy-to-use, antigen presenting cell line, suitable for lipid antigen presentation via CD1d. We also compared BW^STIM to L-CD1d, an immortalized murine fibroblast cell line transduced with human CD1d³⁹. L-CD1d cells express high amounts of CD1d on their surface loaded with agonistic endogenous lipid antigens and are able to stimulate iNKT cells even without addition of α-GalCer^46,47. The advantage of this cell line is that this endogenous lipid antigen can be out-competed by other (endogenous or exogenous e.g. microbial) lipids that can either activate or inhibit our iNKT-reporter cells. Indeed, upon addition of increasing concentrations of α-GalCer, eGFP expression could eventually surpass the high background levels at concentrations above 250 pg/ml α-GalCer.

Low levels of CD1d expression in JE6-1^REP-iNKT cells led to self-presentation resulting in background activation. We could overcome this by knocking out β2M without affecting the sensitivity of the system. Because our reporter system is very easily transfected, it is well-suited for the study of genetic manipulations in TCR receptors and CD1d molecules. Our JE6-1^{REP-iNKT-β2M_KO} reporter cells can be used e.g. for investigations on the structural requirements of CD1d for binding of lipid antigens.

JE6-1^{REP-iNKT-β2M_KO} cells were activated with α-GalCer and the derivatives OCH and 7DW8-5, respectively. Differences in their stimulation capacity were consistent with the results of earlier studies²⁶. This shows that our newly developed system is useful for testing a wide range of iNKT antigens.

Summarizing, we established a modular and convenient human iNKT reporter cell system to facilitate research on immunogenic iNKT lipid ligands. To date, α-GalCer, the iNKT prototypical antigen has been identified as a highly potent activator of iNKT cells and analogs of α-GalCer with a much stronger activation capacity are currently tested in clinical trials. However, knowledge of additional lipid antigens and their immunogenic activation capacity is limited. Utilizing the present iNKT reporter cell system as a high throughput screening tool could help to identify additional lipid candidates relevant for potential therapeutic applications. Moreover, further detailed studies are needed to address important questions such as the relevance of structural features of lipids and their binding affinity to the iNKT-TCR.

Materials and Methods

Cell culture

All cell culture media were supplemented with 10% FBS, 200 mM GlutaMAX, and penicillin/streptomycin unless otherwise stated. Jurkat and BW5147 based cell lines were cultured in RPMI 1640 medium. Murine iNKT cell hybridoma lines (DN32.D3 and N37-1A12) were cultured in Iscove’s Modified Dulbecco’s Medium supplemented with 5% FBS. The murine fibroblast cell line (L-cells) was kindly provided by Dr. Randy Brutkiewicz (Indiana University School of Medicine, Indianapolis, IN, USA) and cultured in DMEM supplemented with 500 μg/mL G418 for selection. All cell lines were cultivated at 37 °C in a humidified atmosphere (95%) containing 5% CO₂.

Flow cytometry

Mouse and human CD1d monomers, tetramers and dextramers (α-GalCer loaded/unloaded, APC-conjugated/Pacific-blue-conjugated/unconjugated) were kindly provided by the NIH Tetramer Core Facility (Atlanta, GA). Monoclonal anti-murine CD28-PE (37.51), CD1d-PE (CD1.1, Ly-38), CD80-PE (16-10A1), CD86-PE (GL-1), anti-human CD28-PE (CD28.2), CD1d-PE (51.1), CD80-PeCys7 (2D10), CD86-PeCys7 (IT2.2), and CD69-APC (FN50) antibodies were purchased from BioLegend (San Diego, CA). Anti-mouse CD45.2-PE (104) antibody was obtained from BD Bioscience (San Jose, CA). Flow cytometry analyses were performed using a BD FACSCanto II flow cytometer (BD Bioscience) and data were analyzed using the FlowJo software (version 10, Tree Star, Ashland, OR, USA).

Generation of a Jurkat based NF-κB-eGFP iNKT reporter cell line

A human iNKT-TCR construct consisting of TCR beta (TCR V-beta chain: GenBank EAW51929.1) and alpha (TCR V-alpha chain: GenBank ABC72374.1) chains separated by a porcine teschovirus-1 2A (P2A) self-cleaving peptide sequence (iNKT-beta_P2A_alpha) was derived by gene synthesis (GeneArt, ThermoFisher, Heidelberg, Germany). The iNKT-beta_P2A_alpha fragment was cloned in frame into a modified lentiviral pHR‐SIN‐BX‐IRES‐Emerald vector, carrying a Thosea asigna virus 2A (T2A) sequence upstream of the puromycin N-acetyl-transferase (PAC) sequence, resulting in a single open reading frame consisting of iNKT-TCR beta, P2A, iNKT-TCR alpha, T2A and PAC (pHR-iNKT-TCR-2A-Puro). Jurkat E6.1 NF-κB::eGFP, a transcriptional reporter cells employing NF-κB-driven expression of eGFP⁴⁵, were transduced with pHR-iNKT-TCR-2A-Puro and selected with puromycin at 1 μg/ml to obtain a uniformly iNKT-TCR positive cell population. Single cell clones were established from the transduced cell pool by limiting dilution and screened for their human iNKT-TCR expression using APC-conjugated CD1d tetramers. Highly expressing clones were chosen for functional tests on plate-bound α-GalCer loaded murine CD1d monomers (for details see below). A clone showing the strongest selective activation (designated JE6-1^REP-iNKT) was used throughout the study.

In Vitro Antigen Presentation Assay

MaxiSorp 96-well ELISA plates were coated with various concentrations (0.16–10.00 μg/ml) of α-GalCer loaded/unloaded murine/human CD1d monomers (kindly provided by NIH Tetramer Core Facility) together with the anti-CD28 antibody or isotype control overnight at 4 °C. For selected experiments, unloaded CD1d was coated and subsequently loaded with lipid antigens by overnight incubation with α-GalCer, OCH and 7DW8-5 diluted in PBS, respectively. Unspecific binding was blocked by addition of 5% fetal bovine serum (FBS) in PBS for two hours at room temperature. After washing with PBS, plates were incubated overnight with 5 × 10⁴ JE6-1^REP-iNKT/murine hybridoma cells in 200 µl of the appropriate medium. After an overnight incubation at 37 °C cells were harvested, analyzed by flow cytometry and the geometric mean of fluorescence intensity (gMFI) was measured for each sample. Activation of murine hybridoma cells was analyzed by evaluating the IL-2 release after 24 hours of stimulation by ELISA according to the manufacturer’s protocol (BD Bioscience).

Antigen self-presentation Assay

Reporter/murine hybridoma cells (5 × 10⁴) were seeded in 100 μl medium. Dilutions of α-GalCer were prepared and added to the wells to obtain final concentration range of 0–20 ng/ml. After 24 hours of incubation, cells were analyzed as described for the in vitro antigen presentation assay.

Generation of BW based stimulator cell lines

Construction of the retroviral pCJK2-CD80 expression construct was described earlier⁴⁴. Using the same strategy as for CD80, human CD1d was PCR amplified and cloned via SfiI into pCJK2. Murine thymoma cells BW5147 were simultaneously transduced with CD1d and CD80. A highly CD1d/CD80 double positive clone was derived by limiting dilution and used throughout the study.

Co-culture assays with BW^STIM and L-CD1d cells

Stimulator cells (BW^PAR/BW^STIM/L-vector/L-CD1d, 5 × 10⁵) were incubated in conical tubes with various concentrations (1.6–2,000 pg/ml) of lipid antigens in the appropriate medium, respectively, for 4 hours at 37 °C in a water bath. After 3 washing steps with PBS, cells were resuspended in 1 ml of medium and seeded in 96-well u-bottom cell culture plates (100 µl/well). Reporter cells (JE6-1^REP/JE6-1^REP-iNKT/N37-1A12/DN32.D3) were added. After an overnight incubation at 37 °C cells were harvested and stained with an anti-mouse CD45 antibody and reporter cell activation was analyzed by FACS. Mouse CD45 positive cells (stimulator cells) were excluded from the analysis and the gMFI was measured for each sample. Median and standard deviation of triplicate wells were determined. For assays using hybridoma cell lines the supernatants were collected and the IL-2 was quantified by ELISA according to the manufacturer’s instruction (BD Bioscience).

Knockout of β2 microglobulin via CRISPR/Cas9 technique

The 20nt single-guide RNA (sgRNA) was selected based on the β2 microglobulin (β2M) mRNA (NM_004048.2) by using the CRISPR design website (http://www.atum.bio). The target sequence 5′-GGCCGAGATGTCTCGCTCCG-3′ was inserted into the lentiCRISPR v2 vector purchased from Addgene (Cat. 52961; Cambridge, MA, USA) according to the protocol described by Zhang et al.^48,49. In detail, the oligos (top: 5′-CACCG-20 nt; bottom: 5′-AAAC-20 nt) were annealed and cloned into the vector via BsmB1 sites. Correct insertion was confirmed by DNA sequencing using the sequencing primer 5′-GTACAAAATACGTGACG-3′. The resulting vector and virus packaging plasmids were transfected into HEK293T cells and cell culture supernatant containing lentiviral particles was used to transduce JE6-1^REP-iNKT. After the selection with pyromycin, single cell clones were established. Genomic DNA from the selected clones was isolated (Gentra Purogene Cell Kit (Qiagen) and sequenced in a two-step PCR reaction described by Brinkmann et al.⁵⁰. The sequence was then analyzed using the TIDE web tool (https://tide.deskgen.com) PMID: 25300484.

Change history

05 November 2019
An amendment to this paper has been published and can be accessed via a link at the top of the paper.

References

Bendelac, A., Killeen, N., Littman, D. R. & Schwartz, R. H. A Subset of CD4+ Thymocytes Selected by MHC Class I Molecules. Science 263, 1774–1778 (1994).
Fowlkes, B. J. et al. A novel population of T-cell receptor alpha beta-bearing thymocytes which predominantly expresses a single V beta gene family. Nature 329, 251–254 (1987).
ADS CAS PubMed Google Scholar
Eberl, G. et al. Tissue-specific segregation of CD1d-dependent and CD1d-independent NK T cells. J. Immunol. 162, 6410–9 (1999).
CAS PubMed Google Scholar
Koseki, H. et al. Predominant use of a particular α-chain in suppressor t cell hybridomas specific for keyhole limpet hemocyanin. Int. Immunol. 1, 557–564 (1989).
CAS PubMed Google Scholar
White, J. et al. Two better cell lines for making hybridomas expressing specific T cell receptors. J. Immunol. 6, 1822–1825 (1989).
Google Scholar
Nyambayar, D. et al. Characterization of NKT-cell hybridomas expressing invariant T-cell antigen receptors. J. Clin. Exp. Hematop. 47, 1–8 (2007).
PubMed Google Scholar
Jukes, J. P. et al. Non-glycosidic compounds can stimulate both human and mouse iNKT cells. Eur. J. Immunol. 46, 1224–1234 (2016).
CAS PubMed PubMed Central Google Scholar
Dellabona, B. P., Padovan, E., Casorati, G., Brockhaus, M. & Lanzavecchia, A. An Invariant Vα24-JαQ/Vβ11 T Cell Receptor Is Expressed in All Individuals by Clonally Expanded CD4-8- T Cells. J Exp Med 180, 1171–1176 (1994).
CAS PubMed Google Scholar
Lee, P. T. et al. Testing the NKT cell hypothesis of human IDDM pathogenesis. J. Clin. Invest. 110, 793–800 (2002).
CAS PubMed PubMed Central Google Scholar
Akbari, O. et al. CD4+ Invariant T-Cell–Receptor + Natural Killer T Cells in Bronchial Asthma. N. Engl. J. Med. 354, 1117–1120 (2006).
CAS PubMed Google Scholar
Jyonouchi, S. et al. Invariant natural killer T cells in children with eosinophilic esophagitis. Clin. Exp. Allergy 44, 58–68 (2014).
CAS PubMed PubMed Central Google Scholar
Terabe, M. & Berzofsky, J. The Role of NKT Cells in Tumor Immunity. Adv. Cancer Res. 101, 277–348 (2008).
CAS PubMed PubMed Central Google Scholar
Crosby, C. M. & Kronenberg, M. Tissue-specific functions of invariant natural killer T cells. Nat. Rev. Immunol. 18, 1–16 (2018).
Google Scholar
Kinjo, Y. et al. Invariant natural killer T cells recognize glycolipids from pathogenic Gram-positive bacteria. Nat. Immunol. 12, 966–74 (2011).
CAS PubMed PubMed Central Google Scholar
Nakamatsu, M. et al. Role of interferon-γ in Vα14+ natural killer T cell-mediated host defense against Streptococcus pneumoniae infection in murine lungs. Microbes Infect. 9, 364–374 (2007).
CAS PubMed Google Scholar
Nieuwenhuis, E. E. S. et al. CD1d-dependent macrophage-mediated clearance of Pseudomonas aeruginosa from lung. Nat. Med. 8, 588–593 (2002).
CAS PubMed Google Scholar
Paget, C. et al. Interleukin-22 is produced by invariant natural killer T lymphocytes during influenza A virus infection: Potential role in protection against lung epithelial damages. J. Biol. Chem. 287, 8816–8829 (2012).
CAS PubMed PubMed Central Google Scholar
Lynch, L. et al. Adipose Tissue Invariant NKT Cells Protect against Diet-Induced Obesity and Metabolic Disorder through Regulatory Cytokine Production. Immunity 37, 574–587 (2012).
CAS PubMed PubMed Central Google Scholar
Wu, L. et al. Activation of invariant natural killer T cells by lipid excess promotes tissue inflammation, insulin resistance, and hepatic steatosis in obese mice. Proc. Natl. Acad. Sci. 109, E1143–E1152 (2012).
CAS PubMed PubMed Central Google Scholar
Mirotti, L. et al. Lipids are required for the development of Brazil nut allergy: the role of mouse and human iNKT cells. Allergy 68, 74–83 (2013).
CAS PubMed Google Scholar
Tordesillas, L. et al. Mechanisms underlying induction of allergic sensitization by Pru p 3. Clin. Exp. Allergy 47, 1398–1408 (2017).
CAS PubMed PubMed Central Google Scholar
Wingender, G. From the Deep Sea to Everywhere: Environmental Antigens for iNKT Cells. Arch. Immunol. Ther. Exp. (Warsz). 64, 291–298 (2016).
CAS PubMed Google Scholar
Morita, M. et al. Structure-activity relationship of alpha-galactosylceramides against B16-bearing mice. J. Med. Chem. 38, 2176–2187 (1995).
CAS PubMed Google Scholar
Rossjohn, J., Pellicci, D. G., Patel, O., Gapin, L. & Godfrey, D. I. Recognition of CD1d-restricted antigens by natural killer T cells. Nat. Rev. Immunol. 12, 845–57 (2012).
CAS PubMed PubMed Central Google Scholar
Kawano, T. CD1d-Restricted and TCR-Mediated Activation of V14 NKT Cells by Glycosylceramides. Science 278, 1626–1629 (1997).
ADS CAS PubMed Google Scholar
Li, X. et al. Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant. Proc. Natl. Acad. Sci. 107, 13010–13015 (2010).
ADS CAS PubMed PubMed Central Google Scholar
Liang, P.-H. et al. Quantitative Microarray Analysis of Intact Glycolipid−CD1d Interaction and Correlation with Cell-Based Cytokine Production. J. Am. Chem. Soc. 130, 12348–12354 (2008).
CAS PubMed PubMed Central Google Scholar
McCarthy, C. et al. The length of lipids bound to human CD1d molecules modulates the affinity of NKT cell TCR and the threshold of NKT cell activation. J. Exp. Med. 204, 1131–1144 (2007).
CAS PubMed PubMed Central Google Scholar
McEwen-Smith, R. M., Salio, M. & Cerundolo, V. The Regulatory Role of Invariant NKT Cells in Tumor Immunity. Cancer Immunol. Res. 3, 425–435 (2015).
CAS PubMed PubMed Central Google Scholar
Motohashi, S. et al. A Phase I-II Study of -Galactosylceramide-Pulsed IL-2/GM-CSF-Cultured Peripheral Blood Mononuclear Cells in Patients with Advanced and Recurrent Non-Small Cell Lung Cancer. J. Immunol. 182, 2492–2501 (2009).
CAS PubMed Google Scholar
Motohashi, S. et al. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer. Clin. Cancer Res. 12, 6079–6086 (2006).
CAS PubMed Google Scholar
Miyamoto, K., Miyake, S. & Yamamura, T. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 413, 531–534 (2001).
ADS CAS PubMed Google Scholar
East, J. E., Sun, W. & Webb, T. J. Artificial Antigen Presenting Cell (aAPC) Mediated Activation and Expansion of Natural Killer T Cells. J. Vis. Exp 70, e433 (2012).
Google Scholar
Jutz, S. et al. A cellular platform for the evaluation of immune checkpoint molecules. Oncotarget 8, 64892–64906 (2017).
PubMed PubMed Central Google Scholar
Rosskopf, S. et al. Creation of an engineered APC system to explore and optimize the presentation of immunodominant peptides of major allergens. Sci. Rep. 6, 31580 (2016).
ADS CAS PubMed PubMed Central Google Scholar
Pellicci, D. G. et al. Differential Recognition of CD1d-α-Galactosyl Ceramide by the Vβ8.2 and Vβ7 Semi-invariant NKT T Cell Receptors. Immunity 31, 47–59 (2009).
CAS PubMed PubMed Central Google Scholar
Lantz, O. An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4-8- T cells in mice and humans. J. Exp. Med. 180, 1097–1106 (1994).
CAS PubMed Google Scholar
Burdin, N. et al. Selective ability of mouse CD1 to present glycolipids: alpha-galactosylceramide specifically stimulates V alpha 14+ NK T lymphocytes. J. Immunol. 161, 3271–3281 (1998).
CAS PubMed Google Scholar
Chen, H. & Paul, W. E. Cultured NK1.1+ CD4+ T cells produce large Cultured NK1.1+ CD4+ T Cells Produce Large Amounts of 11-4 and IFN-7 Upon Activation by Anti-CD3 or CD1. J Immunol. 159, 2240–2249 (1997).
CAS PubMed Google Scholar
Bendelac, A., Savage, P. B. & Teyton, L. The Biology of NKT Cells. Annu. Rev. Immunol. 25, 297–336 (2007).
CAS PubMed Google Scholar
Engel, I. et al. Innate-like functions of natural killer T cell subsets result from highly divergent gene programs. Nat. Immunol. 17, 1–21 (2016).
Google Scholar
Zapala, L. et al. Optimization of activation requirements of immature mouse dendritic JAWSII cells for in vivo application. Oncol. Rep. 25, 831–840 (2011).
CAS PubMed Google Scholar
Rizvi, Z. A., Puri, N. & Saxena, R. K. In Vitro Lipid antigen presentation through CD1d pathway in mouse lung epithelial cells, macrophages and dendritic cells and its suppression by poly-dispersed single-walled carbon nanotubes. Toxicol. Vitr. 29, 1275–1282 (2015).
CAS Google Scholar
Leitner, J. et al. T cell stimulator cells, an efficient and versatile cellular system to assess the role of costimulatory ligands in the activation of human T cells. J. Immunol. Methods 362, 131–141 (2010).
CAS PubMed PubMed Central Google Scholar
Jutz, S. et al. Assessment of costimulation and coinhibition in a triple parameter T cell reporter line: Simultaneous measurement of NF-κB, NFAT and AP-1. J. Immunol. Methods 430, 10–20 (2016).
CAS PubMed Google Scholar
Webb, T. J. et al. Molecular identification of GD3 as a suppressor of the innate immune response in ovarian cancer. Cancer Res. 72, 3744–3752 (2012).
CAS PubMed PubMed Central Google Scholar
Webb, T. J. R. et al. Inhibition of CD1d1-mediated antigen presentation by the vaccinia virus B1R and H5R molecules. Eur. J. Immunol. 36, 2595–2600 (2006).
CAS PubMed Google Scholar
Sanjana, N. E., Shalem, O. & Zhang, F. Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods 7, 399–402 (2015).
Google Scholar
Shalem, O. et al. Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells. Science 343, 84–87 (2014).
ADS CAS PubMed Google Scholar
Brinkman, E. K. et al. Easy quantification of template-directed CRISPR/Cas9 editing. Nucleic Acids Res. 46, e58 (2018).

Download references

Acknowledgements

We wish to thank Dr. Shinya Sakaguchi for providing mouse CD1d/α-GalCer dextramers. The authors also thank the NIH Tetramer Core Facility for providing CD1d monomers and tetramers. This work was partially funded by the Austrian Science Fund (FWF): DK W 1248-B13 for PH and SFB F4603 for KHS.

Author information

Wolfgang Paster
Present address: Children’s Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria

Authors and Affiliations

Department of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria
Piotr Humeniuk, Sabine Geiselhart & Karin Hoffmann-Sommergruber
Institute of Immunology, Division of Immune Receptors and T cell Activation, Medical University of Vienna, Vienna, Austria
Claire Battin, Peter Steinberger & Wolfgang Paster
Department of Microbiology & Immunology, University of Maryland School of Medicine, Baltimore, USA
Tonya Webb

Authors

Piotr Humeniuk
View author publications
You can also search for this author in PubMed Google Scholar
Sabine Geiselhart
View author publications
You can also search for this author in PubMed Google Scholar
Claire Battin
View author publications
You can also search for this author in PubMed Google Scholar
Tonya Webb
View author publications
You can also search for this author in PubMed Google Scholar
Peter Steinberger
View author publications
You can also search for this author in PubMed Google Scholar
Wolfgang Paster
View author publications
You can also search for this author in PubMed Google Scholar
Karin Hoffmann-Sommergruber
View author publications
You can also search for this author in PubMed Google Scholar

Contributions

The study was designed by K.H.S., P.S., T.W., and W.P. Experiments were performed by P.H., S.G., C.B. and W.P. P.H., S.G., W.P. and C.B. drafted the manuscript and all co-authors provided input to the article draft. All the authors critically revised the manuscript for intellectual content and read and approved the final manuscript.

Corresponding authors

Correspondence to Wolfgang Paster or Karin Hoffmann-Sommergruber.

Ethics declarations

Competing Interests

T.W. is the CEO of WebbCures, LLC and is on the scientific advisory board for Immunaccel Labs. All the other authors declare no competing interests.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Cite this article

Humeniuk, P., Geiselhart, S., Battin, C. et al. Generation of a Jurkat-based fluorescent reporter cell line to evaluate lipid antigen interaction with the human iNKT cell receptor. Sci Rep 9, 7426 (2019). https://doi.org/10.1038/s41598-019-43529-4

Download citation

Received: 04 March 2019
Accepted: 23 April 2019
Published: 15 May 2019
DOI: https://doi.org/10.1038/s41598-019-43529-4

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.